We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Bayer Aktiengesellschaft (PK) | USOTC:BAYRY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 7.60 | 7.59 | 7.68 | 7.69 | 7.59 | 7.66 | 2,551,609 | 21:30:14 |
From May 2021 to May 2024
By Ed Frankl
Bayer AG said Monday that it has filed a petition to the U.S. Supreme Court for review of a case in which a plaintiff said its glyphosate weedkiller caused cancer.
The German conglomerate, through its subsidiary Monsanto, filed a petition for a Writ of Certiorari--which requests the Supreme Court to order a lower court to send up the suit for review--for a case concerning a California resident named Edwin Hardeman, who said that his lymphoma was caused by the weedkiller Roundup.
According to Bayer, which previously flagged its intention to file the petition, the decision could affect thousands of other suits and influence others still pending in the U.S.
Bayer said in late July that it would set aside a further $4.5 billion in provisions to end litigation around its Roundup weedkiller, in the event of an unfavorable Supreme Court ruling related to the Hardeman case.
Write to Ed Frankl at edward.frankl@dowjones.com
(END) Dow Jones Newswires
August 16, 2021 11:25 ET (15:25 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Bayer Aktiengesellschaft (PK) Chart |
1 Month Bayer Aktiengesellschaft (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
